Nadolol |
Catalog No.GC39740
One-Click Copy Product Info
|
Nadolol is a non-selective and orally active beta-adrenergic antagonist with antihypertensive and antiarrhythmic activities.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 42200-33-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Nadolol is a non-selective and orally active beta-adrenergic antagonist with antihypertensive and antiarrhythmic activities [1]. Nadolol can inhibit the calmodulin-activated Ca2+-ATPase of human erythrocyte membranes [2]. Nadolol has been widely used to reduce heart rate at rest and during exercise and to reduce plasma renin activity[3].
In vitro, Nadolol treatment (10µM) for 24 hours significantly increased Gαs protein levels and enhanced basal cAMP levels in β2AR-expressing HEK 293 cells[4]. Treatment with 250µM Nadolol for 48h induced apoptosis and decreased mitochondrial membrane potential in A549 cells[5].
In vivo, Nadolol treatment via intraperitoneal injection at a single dose of 20mg/kg significantly reduced the number and area of lung metastases in a B16F10 cell-xenograft mouse model under acute social stress during 15 days[6]. A single dose of 5mg/kg Nadolol was injected intraperitoneally at 1h after reperfusion, which significantly reversed the increases in neurological deficit score and infarct volume in the ischemic stroke rats[7].
References:
[1] Kalsoom S, Zamir A, Rehman A U, et al. Clinical pharmacokinetics of nadolol: A systematic review[J]. Journal of Clinical Pharmacy and Therapeutics, 2022, 47(10): 1506-1516.
[2] Meltzer H L, Kassir S. Inhibition of calmodulin-activated Ca2+-ATPase by propranolol and nadolol[J]. Biochimica et Biophysica Acta (BBA)-General Subjects, 1983, 755(3): 452-456.
[3] Heel R C, Brogden R N, Pakes G E, et al. Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris[J]. Drugs, 1980, 20(1): 1-23.
[4] Peng H, Bond R A, Knoll B J. The effects of acute and chronic nadolol treatment on β2AR signaling in HEK293 cells[J]. Naunyn-Schmiedeberg's archives of pharmacology, 2011, 383(2): 209-216.
[5] Kavakcıoğlu Yardımcı B, Geyikoglu F, Aysin F, et al. The cytotoxic and apoptotic effects of beta-blockers with different selectivity on cancerous and healthy lung cell lines[J]. Molecular Biology Reports, 2021, 48(5): 4009-4019.
[6] Vegas O, Garmendia L, Arregi A, et al. Effects of antalarmin and nadolol on the relationship between social stress and pulmonary metastasis development in male OF1 mice[J]. Behavioural brain research, 2009, 205(1): 200-206.
[7] Yang X Y, Zhu W J, Chen D, et al. Nadolol Attenuates Brain Cell Ferroptosis in Ischemic Stroke Rats by Targeting the HOIL-1/IRP2 Pathway[J]. CNS & Neurological Disorders-Drug Targets, 2025, 24(5): 397-408.
| Cell experiment [1]: | |
Cell lines | A549 cells |
Preparation Method | A549 cells were cultured in DMEM/F12 medium supplemented with 10% fetal bovine serum (FBS) and antibiotics (penicillin 100U/ml, streptomycin 0.1mg/ml) under normal conditions (5% CO2 with 95% humidified air). A549 cells (1×104 per well) were inoculated in a 96-well cell culture plate and incubated at 37°C with 5% CO2 for 24h. Then, the cells were treated with different concentrations of Nadolol (5, 10, 25, 50, 100, 150, 200, and 250µM) for 48h, respectively, and cell viability was measured. |
Reaction Conditions | 5, 10, 25, 50, 100, 150, 200, and 250µM; 48h |
Applications | Nadolol treatment reduced the cell viability of A549 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male Sprague-Dawley (SD) rats |
Preparation Method | Male Sprague-Dawley (SD) rats (250-300g) were housed in groups of 3-5 rats per cage with free access to food and water ad libitum. The 12-h light/dark cycles were maintained throughout the duration of animal housing, with light periods beginning consistently at 7:00 am. Before surgery, the rats were fasted overnight but were free to drink tap water. The ischemic stroke rat model was constructed by Middle Cerebral Artery Occlusion (MCAO). Rats were randomly distributed into four groups (n=12 per group): (1) the sham group, (2) the stroke group, (3) the stroke+Nadolol group, rats received Nadolol (5mg/kg; i.p.) at 1h after reperfusion, and (4) the stroke+vehicle group, rats received DMSO (i.p.) at 1h after reperfusion. Following the end of reperfusion, an assessment of the neurological deficit score was first conducted, and then the rats were executed under anesthesia. The brain tissues were preserved for infarct volume measurement. |
Dosage form | 5mg/kg for once; i.p. |
Applications | Nadolol treatment reversed the increases in neurological deficit score and infarct volume in the ischemic stroke rats. |
References: | |
| Cas No. | 42200-33-9 | SDF | |
| Canonical SMILES | OC1CC2=C(C(OCC(O)CNC(C)(C)C)=CC=C2)CC1O | ||
| Formula | C17H27NO4 | M.Wt | 309.4 |
| Solubility | Methanol: 250 mg/mL (808.02 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2321 mL | 16.1603 mL | 32.3206 mL |
| 5 mM | 646.4 μL | 3.2321 mL | 6.4641 mL |
| 10 mM | 323.2 μL | 1.616 mL | 3.2321 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)